| scholarly article | Q13442814 |
| P2093 | author name string | Wisniewski HM | |
| Dalton AJ | |||
| Wisniewski KE | |||
| McLachlan C | |||
| Wen GY | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 957-961 | |
| P577 | publication date | 1985-07-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Alzheimer's disease in Down's syndrome: clinicopathologic studies | |
| P478 | volume | 35 |
| Q57719466 | A Protective Effect of Apolipoprotein E e2 Allele on Dementia in Down’s Syndrome |
| Q48499583 | A Skew-t space-varying regression model for the spectral analysis of resting state brain activity. |
| Q40981910 | A beta A4 amyloid precursor protein gene and Alzheimer's disease |
| Q28681184 | A decade and a half of protein intrinsic disorder: biology still waits for physics |
| Q26798983 | A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome |
| Q52013436 | A mouse model for Down syndrome exhibits learning and behaviour deficits. |
| Q33628428 | A pathological study of the association between Lewy body disease and Alzheimer's disease |
| Q29999430 | A voxel-based morphometric study of nondemented adults with Down Syndrome |
| Q36148727 | Acute neuropsychiatric disorders in adolescents and young adults with Down syndrome: Japanese case reports |
| Q53209648 | Age-associated chromosome 21 loss in Down syndrome: possible relevance to mosaicism and Alzheimer disease. |
| Q69300892 | Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain |
| Q39403080 | Aluminum and neurodegenerative disease: therapeutic implications |
| Q37603746 | Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment |
| Q37967694 | Alzheimer's - Looking beyond plaques |
| Q37272133 | Alzheimer's Disease in Adults with Down Syndrome |
| Q39479856 | Alzheimer's disease in Down's syndrome. A review |
| Q53324220 | Alzheimer's disease in women. |
| Q37376532 | Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases |
| Q42993144 | Amyloid precursor protein metabolism in fibroblasts from individuals with one, two or three copies of the amyloid precursor protein (APP) gene |
| Q34039695 | Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance |
| Q35166482 | Amyloid-β efflux from the central nervous system into the plasma |
| Q37543845 | Aneuploidy: from a physiological mechanism of variance to Down syndrome |
| Q42486904 | Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome |
| Q53298189 | Autoimmune thyroiditis associated with mild "subclinical" hypothyroidism in adults with Down syndrome: a comparison of patients with and without manifestations of Alzheimer disease. |
| Q47823260 | CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation (MCS). |
| Q46545035 | CASP3 protein expression by flow cytometry in Down's syndrome subjects. |
| Q35146030 | Causative and susceptibility genes for Alzheimer's disease: a review. |
| Q58271755 | Cerebral amyloid angiopathy-related hemorrhage in a middle-aged patient with Down's syndrome |
| Q46173614 | Changes in calcium homeostasis during aging and Alzheimer's disease |
| Q35842893 | Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome |
| Q92603531 | Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer's Disease and in Down Syndrome Dementia |
| Q69893508 | Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome |
| Q39480777 | Clinical expression of Alzheimer's disease in Down's syndrome. |
| Q37279515 | Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. |
| Q41198458 | Cognitive functions in adult Down's syndrome. |
| Q48074756 | Computerised cognitive testing of individuals with Down's syndrome and Alzheimer's disease |
| Q52194287 | Contrast sensitivity in infants and children with Down syndrome. |
| Q37404602 | Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors |
| Q35098038 | DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes |
| Q26745413 | DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome |
| Q37152915 | Dementia in Down's syndrome: an MRI comparison with Alzheimer's disease in the general population |
| Q51961412 | Dementia in people with Down's syndrome. |
| Q46163302 | Dendrites, dementia and the Down syndrome. |
| Q48334770 | Detection of Lewy bodies in Trisomy 21 (Down's syndrome). |
| Q36972797 | Diagnostic and pharmacological approaches in Alzheimer's disease |
| Q48722378 | Differential expression of PARP1 mRNA in leucocytes of patients with Down's syndrome. |
| Q39480888 | Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome |
| Q37113208 | Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis |
| Q33674369 | Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice |
| Q49497621 | Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. |
| Q37734742 | Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome |
| Q46257307 | Early senile plaques in Alzheimer's disease demonstrated by histochemistry, immunocytochemistry, and electron microscopy. |
| Q24303677 | Effect of Anticoagulants on Amyloid β-Protein Precursor and Amyloid Beta Levels in Plasma |
| Q36522433 | Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome |
| Q24619170 | Emerging Pharmacotherapies for Neurodevelopmental Disorders |
| Q39058736 | Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease? |
| Q42494316 | Evidence for an interferon-related inflammatory reaction in the trisomy 16 mouse brain leading to caspase-1-mediated neuronal apoptosis |
| Q33667855 | Excess betaCTF, not Abeta: the culprit in Alzheimer-related endocytic dysfunction |
| Q95804953 | Expression of LDOC1 mRNA in leucocytes of patients with Down's syndrome |
| Q33589170 | Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history |
| Q48207597 | Failure of familial Alzheimer's disease to segregate with the A4-amyloid gene in several European families. |
| Q35977798 | Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia |
| Q39324113 | GABAergic hyperinnervation of dentate granule cells in the Ts65Dn mouse model of down syndrome: Exploring the role of App. |
| Q48535645 | Gene expression profiling and qRT-PCR expression of RRP1B, PCNT, KIF21A and ADRB2 in leucocytes of Down's syndrome subjects. |
| Q40506355 | Generation of Rabbit Monoclonal Antibody to Amyloid-β38 (Aβ38): Increased Plasma Aβ38 Levels in Down Syndrome |
| Q48499322 | Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Abeta peptide. |
| Q37593845 | Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome |
| Q35094704 | Genetics of Vascular Dementia |
| Q35830671 | Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease |
| Q37613081 | Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. |
| Q37407381 | In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. |
| Q42993141 | In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. |
| Q52172858 | Increased levels of tau-like protein in patients with Down syndrome. |
| Q74313854 | Increased plasma amyloid beta protein 1-42 levels in Down syndrome |
| Q36980997 | Integrated miRNA and mRNA expression profiling in fetal hippocampus with Down syndrome |
| Q46899115 | Intrinsically disordered protein from a pathogenic mesophile Mycobacterium tuberculosis adopts structured conformation at high temperature |
| Q35135581 | Intrinsically disordered proteins and their (disordered) proteomes in neurodegenerative disorders |
| Q39649610 | Involvement of notch signaling pathway in amyloid precursor protein induced glial differentiation. |
| Q34917679 | Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome? |
| Q42526357 | Long survival in Fukuyama congenital muscular dystrophy: occurrence of neurofibrillary tangles in the nucleus basalis of Meynert and locus ceruleus |
| Q92236496 | Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome |
| Q36522425 | Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. |
| Q37647989 | Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice. |
| Q33643589 | Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome |
| Q34046354 | Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice |
| Q55506979 | Molecular Mechanisms in Alzheimer's Disease. |
| Q34631864 | Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides |
| Q26750717 | Molecular genetics of early-onset Alzheimer's disease revisited |
| Q33674852 | Molecular genetics of human chromosome 21. |
| Q48050089 | More than just tails: intrinsic disorder in histone proteins |
| Q41054361 | Myoclonic epilepsy of late onset in trisomy 21. |
| Q38303183 | Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation |
| Q31032564 | Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease |
| Q30051683 | Neuroimaging of individuals with Down’s syndrome at-risk for dementia: Evidence for possible compensatory events |
| Q35009772 | Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease |
| Q35815212 | Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis |
| Q52172749 | Neuronal loss and beta-amyloid removal in the amygdala of people with Down syndrome. |
| Q34112868 | Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study |
| Q92399659 | Neuropathological correlates of amyloid PET imaging in Down syndrome |
| Q33775384 | Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. |
| Q26741247 | Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease |
| Q37500309 | New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome |
| Q53341132 | On chronological changes in the basic EEG rhythm in persons with Down syndrome - with special reference to slowing of alpha waves. |
| Q41906667 | On the intrinsic disorder status of the major players in programmed cell death pathways |
| Q41153426 | Parkinsonian features in advanced Down’s syndrome |
| Q42197902 | Patterns of differences in wayfinding performance and correlations among abilities between persons with and without Down syndrome and typically developing children |
| Q34204889 | Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome |
| Q73417757 | Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome |
| Q35940119 | Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease |
| Q35681808 | Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome |
| Q34174220 | Preventing dementia |
| Q34658251 | Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease |
| Q37950254 | Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. |
| Q36983500 | Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain |
| Q36379453 | RCAN1 links impaired neurotrophin trafficking to aberrant development of the sympathetic nervous system in Down syndrome |
| Q48291777 | Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's beta-amyloid precursor protein |
| Q38982671 | Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome |
| Q33830518 | Recent insights into the molecular genetics of dementia |
| Q53184725 | Red cell superoxide dismutase, glutathione peroxidase and catalase in Down syndrome patients with and without manifestations of Alzheimer disease. |
| Q36390685 | Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. |
| Q53303249 | Regional cerebral blood flow in Down's syndrome. |
| Q37476530 | Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. |
| Q48787630 | Seizures in children with Down syndrome: etiology, characteristics and outcome. |
| Q48715374 | Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease |
| Q46529505 | Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease |
| Q37137397 | Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. |
| Q36020398 | Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept |
| Q37683060 | The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome |
| Q42470521 | The amygdala in down's syndrome and familial Alzheimer's disease: Four clinicopathological case report |
| Q81651107 | The genetics of Alzheimer's disease |
| Q36908531 | The impact of aging on eating, drinking, and swallowing function in people with Down's syndrome |
| Q33867210 | The mouse model of Down syndrome Ts65Dn presents visual deficits as assessed by pattern visual evoked potentials |
| Q59886027 | The psychiatry of elderly people with mental handicaps |
| Q44505340 | The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide |
| Q33971345 | The role of complement in Alzheimer's disease pathology |
| Q33629702 | The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome |
| Q41838706 | The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis |
| Q64989338 | The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods. |
| Q78819278 | Traffic at the intersection of neurotrophic factor signaling and neurodegeneration |
| Q33844718 | Transgenic models of Alzheimer's disease: learning from animals |
| Q55418661 | Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. |
| Q48503614 | Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. |
| Q30385084 | Understanding protein non-folding. |
| Q37662773 | Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. |
| Q38984026 | Upregulation of SET expression by BACE1 and its implications in Down syndrome |
| Q36957710 | Using mouse models to explore genotype-phenotype relationship in Down syndrome. |
| Q38038399 | What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders |
| Q36004329 | Working memory in the aged Ts65Dn mouse, a model for Down syndrome |
| Q30498160 | β-Amyloid impairs axonal BDNF retrograde trafficking |
Search more.